

Product Description

Joint^{sol}[®]

INDICATIONS

Joint^{sol}[®] is a product recommended for:

- The maintenance of joints and bones structures.
- The treatment of joint inflammations such as osteoarthritis.
- The prevention of bone and joint degeneration.

COMPOSITION

Joint^{sol}[®] is a product that combines a special rose hip extract (*Rosa canina* L.), embedded in a matrix of hydrolysed collagen. Due to the synergistic action of its components, this blend shows superior efficacy on joint problems than the treatment with each ingredient separately.

Joint^{sol}[®] reduces the usual recommended collagen dose, thanks to the synergistic action of the special rose hip extract.

DESCRIPTION

Several in vitro experiments and clinical studies showed that the skin of the rose hip fruit contains remarkable anti-inflammatory active principles.

On the other hand, several clinical trials using hydrolysed collagen have shown a stimulating action of the cartilage and bone cells activity due to the presence of collagen peptides.

Scientific and clinical dates show that the combination of the special extract of rose hip skins and hydrolysed collagen of Joint^{sol}[®] is an effective and safe treatment for joints and bones diseases.

OBSERVATIONAL STUDIES

Two clinical studies have been carried out with 30 and 108 patients respectively aged 60 and 65 years suffering from arthritis of the knee, with a daily dose of 5.5 g of Joint^{sol}[®].

Both studies took 12 weeks evaluating at different time periods the levels of mobility, pain and quality of life. In both studies Joint^{sol}[®] showed an improvement of the quality of life of patients, reducing the degree of pain during the activity periods. The reduction of pain symptoms was obtained within three weeks of starting treatment.

The pain gradually decreases throughout the study obtaining a significant reduction at 12 weeks of treatment.



The overall rating on improving knee mobility was 79.8%. This improvement allowed patients to reduce the consumption of anti-inflammatory drugs in 15.5%.




Fig 1. Evaluation of the degree of pain reduction in patients treated with **Jointsol®** at 4, 8 and 12 weeks from starting day.




Fig. 2 Results of radiological parameters: deformation, osteochondrosis and joint space in patients treated with **Jointsol®** in the last visit compared to the first one.

CONCLUSIONS

The two studies carried out in patients suffering from osteoarthritis and treated with **jointsol®** have shown:

- Improvement of pain symptoms of joints at the first 3 weeks of the beginning of treatment. This improvement was observed during the activity phase.
- A significant reduction of joint pain at week 4.
- A significant increase in joint mobility, totally evident after 12 weeks of treatment.

These results confirm the efficacy of **Jointsol®** for the treatment and regeneration of joints as well as preventing joint degeneration.

The combination of the stimulatory effect of hydrolysed collagen on cartilage growth with the anti-inflammatory effect of the special aqueous extract of rose hip makes **Jointsol®** a key product in joint health.

RECOMMENDED DOSE

We recommend a daily dose of 6.5 g of **Jointsol®** containing 5 g of hydrolysed collagen type I plus 0.5 g of special rose hip extract)